^
    Back
    Association details:
    Biomarker:HLA-DQB1*03:01
    Cancer:Urothelial Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer Sci
    Title:

    Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab

    Published date:
    07/18/2022
    Excerpt:
    ...108 patients with chemoresistant metastatic or locally advanced UC treated with pembrolizumab….Patients with the HLA-DQB1*03:01 allele had significantly lower disease control rates than patients without the allele (17.4% vs. 53.8%, p = 0.002)…
    DOI:
    10.1111/cas.15488